Influenza vaccination of dialysis patients: Cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults

Nephrology Dialysis Transplantation

Volumn 18, Issue 4, 2003, Pages 777-781

  Antonen, Jaakko A ^a   Pyhälä, Reijo ^b   Hannula, Päivi M ^a   Ala Houhala, Ilpo O ^a   Santanen, Riitta ^b   Ikonen, Niina ^b   Saha, Heikki H T ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cross reactivity; Haemodialysis; Influenza; Vaccination; Vitamin D

Indexed keywords

CROSS REACTING ANTIBODY; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY RESPONSE; ANTIGENIC VARIATION; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; HEART DISEASE; HEMODIALYSIS; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL;

ADULT; ANTIBODIES, VIRAL; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY FAILURE, CHRONIC; MALE; PROBABILITY; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; VITAMIN D;

EID: 0037385419     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg012     Document Type: Article

References (20)

1. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay JA, eds. Textbook of Influenza. Blackwell Science, Oxford, UK, 1998: 358-372
2. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758-1764
3. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet 1992; 22: 434-446
4. Cappel R, Van Beers D, Liesnard C, Dratwa M. Impaired humoral and cell-mediated immune response in dialyzed patients after influenza vaccination. Nephron 1983; 33: 21-25
5. Antonen JA, Hannula PM, Pyhälä R, Saha HHT, Ala-Houbala IO, Pasternack AI. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 2000; 86: 56-61
6. Brydak LB, Roszkowska-Blaim M, Machala M, Leszczynska B, Sieniawska M. Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases. Vaccine 2000; 18: 3280-3286
7. Brokstad KA, Cox RJ, Major D, Wood JM, Haaheim LR. Cross-reactivity but no avidity change of the serum antibody response after influenza vaccination. Vaccine 1995; 13: 1522-1528
8. de Jong JC, Beyer WEP, Palache AM, Rimmelzwaan GF, Osterhaus ADME. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61: 94-99
9. Girndt M, Sester M, Sester U, Kaul U, Köhler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001; 78: 206-211
10. Pyhälä R, Alanko S, Forsten T et al. Early kinetics of antibody response to inactivated inluenza vaccine. Clin Diagn Virol 1994; 1: 271-278
11. Pyhälä R, Ikonen N, Santanen R et al. Vaccination-induced HI antibody response to intraepidemic influenza A (H3N2) virus variants of the 1996-1997 epidemic season. J Med Virol 2001; 65: 584-589
12. Pyhälä R, Haanpää M, Kleemola M, Tervahauta R, Visakorpi R, Kinnunen L. Acceptable protective efficacy of influenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match. Vaccine 2001; 19: 3253-3260
13. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990; 64: 1808-1811
14. Robertson JS. Clinical influenza virus and the embryonated hen's eggs. Rev Med Virol 1993; 3: 97-106
15. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (revision) 1997 March 12: CPMP/BWP/214/96
16. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann Rev Biochem 2000; 69: 531-569
17. Gross PA, Hermogesen AW, Sacks HS, Lau J, Levandowski RA. The efficacy of inluenza vaccine in elderly persons: meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-527
18. Beyer WEP, Versluis DJ, Kramer P, Diderich PPN, Weimar W, Masurel N. Trivalent influenza vaccine in haemodialysis: impaired seroresponse with differences fot A-H3N2 and A-H1N1 vaccine components. Vaccine 1987; 5: 43-48
19. Peces R, Laures AS. Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody response. Nephron 2001; 89: 172-176
20. Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 1999; 159: 182-188